Physician profile
Alan L Keiser
NPI 1982786786
$919.21
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.84 · 2020: $175 · 2021: $733.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $126.29 | 2021 | |
| Lilly USA, LLC | $124.00 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $101.52 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.36 | 2020-2021 | |
| Novo Nordisk INC | $81.24 | 2020-2021 | |
| Amgen INC. | $61.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $60.62 | 2021 | |
| Pfizer INC. | $56.19 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $36.31 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $34.77 | 2021 | |
| Glaxosmithkline, LLC. | $21.65 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.36 | 2021 | |
| Abbott Laboratories | $18.24 | 2021 | |
| Medtronic, INC. | $18.08 | 2021 | |
| Bausch Health US, LLC | $17.67 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.50 | 2021 | |
| Alexion Pharmaceuticals, INC. | $15.12 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.09 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.72 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Keiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.